These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 3056281)

  • 1. T-lymphocyte subsets in the lesional skin of allogeneic and autologous bone marrow transplant patients.
    Paller AS; Nelson A; Steffen L; Gottschalk L; Kaizer H
    Arch Dermatol; 1988 Dec; 124(12):1795-801. PubMed ID: 3056281
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transition of T cell receptor gamma/delta expressing double negative (CD4-/CD8-) lymphocytes after allogeneic bone marrow transplantation.
    Yabe M; Yabe H; Hattori K; Hinohara T; Morimoto T; Kato S; Kusunoki A
    Bone Marrow Transplant; 1994 Nov; 14(5):741-6. PubMed ID: 7889006
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Skin biopsy in allogeneic and autologous bone marrow transplant patients: a histologic and immunohistochemical study and review of the literature.
    Esteban JM; Somlo G
    Mod Pathol; 1995 Jan; 8(1):59-64. PubMed ID: 7731943
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The phenotype and reconstitution of immunoregulatory T cell subsets after T cell-depleted allogeneic and autologous bone marrow transplantation.
    Sugita K; Soiffer RJ; Murray C; Schlossman SF; Ritz J; Morimoto C
    Transplantation; 1994 May; 57(10):1465-73. PubMed ID: 7910987
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Generation of CD8 cytolytic T cells early after autologous or allogeneic bone marrow transplantation.
    Charmot D; Ragueneau M; Olive D; Maraninchi D; Mawas C
    Bone Marrow Transplant; 1987 Aug; 2(2):183-94. PubMed ID: 2901879
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of T cell activation antigen CD134 (OX40) has no predictive value for the occurrence or response to therapy of acute graft-versus-host disease in partial T cell-depleted bone marrow transplantation.
    Gadisseur AP; Gratama JW; Lamers C; van Esser JW; Bolhuis RL; Cornelissen JJ
    Bone Marrow Transplant; 1999 May; 23(10):1013-7. PubMed ID: 10373067
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cyclosporin A-induced graft-versus-host disease following autologous bone marrow and stem cell transplantation in hematological malignancies of childhood.
    Gruhn B; Häfer R; Kosmehl H; Fuchs D; Zintl F
    Bone Marrow Transplant; 1998 May; 21(9):901-7. PubMed ID: 9613782
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cell populations and adhesion molecules expression in conjunctiva before and after bone marrow transplantation.
    Rojas B; Cuhna R; Zafirakis P; Ramirez JM; Lizan-garciía M; Zhao T; Foster CS
    Exp Eye Res; 2005 Sep; 81(3):313-25. PubMed ID: 16129099
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Keratinocyte apoptosis following bone marrow transplantation: evidence for CTL-dependent and -independent pathways.
    Jerome KR; Conyers SJ; Hansen DA; Zebala JA
    Bone Marrow Transplant; 1998 Aug; 22(4):359-66. PubMed ID: 9722071
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Close simulation of acute graft-versus-host disease by interleukin-2 administered after autologous bone marrow transplantation for hematologic malignancy.
    Massumoto C; Benyunes MC; Sale G; Beauchamp M; York A; Thompson JA; Buckner CD; Fefer A
    Bone Marrow Transplant; 1996 Mar; 17(3):351-6. PubMed ID: 8704686
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased numbers of CD8+CD11+, CD8+CD11- and CD8+Leu7+ cells in patients with chronic graft-versus-host disease after allogeneic bone marrow transplantation.
    Yabe H; Yabe M; Kato S; Kimura M; Iwaki K
    Bone Marrow Transplant; 1990 May; 5(5):295-300. PubMed ID: 1693537
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Graft-vs.-host and graft-vs.-leukemia reactions after delayed infusions of donor T-subsets.
    Johnson BD; Becker EE; Truitt RL
    Biol Blood Marrow Transplant; 1999; 5(3):123-32. PubMed ID: 10392958
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevention of graft-versus-host disease in high risk patients by depletion of CD4+ and reduction of CD8+ lymphocytes in the marrow graft.
    Herrera C; Torres A; García-Castellano JM; Roman J; Martin C; Serrano J; Falcon M; Alvarez MA; Gomez P; Martinez F
    Bone Marrow Transplant; 1999 Mar; 23(5):443-50. PubMed ID: 10100557
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human herpes virus-6 infection in marrow graft recipients: role in pathogenesis of graft-versus-host disease. Newcastle upon Tyne Bone Marrow Transport Group.
    Appleton AL; Sviland L; Peiris JS; Taylor CE; Wilkes J; Green MA; Pearson AD; Kelly PJ; Malcolm AJ; Proctor SJ
    Bone Marrow Transplant; 1995 Dec; 16(6):777-82. PubMed ID: 8750269
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Kinetic of regulatory CD25high and activated CD134+ (OX40) T lymphocytes during acute and chronic graft-versus-host disease after allogeneic bone marrow transplantation.
    Sanchez J; Casaño J; Alvarez MA; Roman-Gomez J; Martin C; Martinez F; Gomez P; Serrano J; Herrera C; Torres A
    Br J Haematol; 2004 Sep; 126(5):697-703. PubMed ID: 15327522
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alloreactivity and the predictive value of anti-recipient specific interleukin 2 producing helper T lymphocyte precursor frequencies for alloreactivity after bone marrow transplantation.
    Russell CA
    Dan Med Bull; 2002 May; 49(2):89-108. PubMed ID: 12064093
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunomagnetic CD4+ and CD8+ cell depletion for patients at high risk for severe acute GVHD.
    Jansen J; Hanks S; Akard LP; Thompson JM; Burns S; Chang Q; English D; Garrett P
    Bone Marrow Transplant; 1996 Mar; 17(3):377-82. PubMed ID: 8704690
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Measurement of recipient-specific alloreactivity: is GVHD predictable?
    Theobald M; Bunjes D; Nierle T; Arnold R; Heimpel H
    Bone Marrow Transplant; 1993; 12 Suppl 3():S18-23. PubMed ID: 8124251
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inflammatory cells in graft-versus-host disease on the rectum: immunopathologic analysis.
    Weisdorf SA; Roy J; Snover D; Platt JL; Weisdorf DJ
    Bone Marrow Transplant; 1991 Apr; 7(4):297-301. PubMed ID: 2070136
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.